News

October 2, 2025

NOF to Exhibit and Present at SITC 2025 (Nov 7 – 8)

Tokyo, Japan — NOF CORPORATION is pleased to announce its participation in the upcoming SITC 2025, which will be held at the Gaylord Resort & Convention Center, National Harbor, MD U.S.A. from November 5 to 9.

As a part of the event, NOF CORPORATION will showcase its products for Drug Delivery System at Booth #709 on November 7 and 8.
NOF CORPORATION invites attendees to visit booth #709 to explore the innovative drug delivery solutions, to engage with their experts, and to discuss potential collaborations.

Additionally, Satoshi Kishida and Minori Takino, Research scientists at NOF CORPORATION, will each deliver poster presentations on the following topics.

Poster Presentation 1

Title
Development and evaluation of novel cleavable pendant type PEG linkers for ADCs

Date & Time
November 7 from 10:00 to 19:00, EST

Poster Number
#953

Speaker
Minori Takino, Research scientist, NOF CORPORATION

Abstract
In recent years, Antibody-drug conjugates (ADCs) are one of the fastest growing therapeutic modalities in the field of cancer treatment. A high drug-to-antibody ratio (DAR) is a desirable characteristic because it increases the efficacy. However, preparing high DAR ADCs often lead to issues such as aggregation and decreased antibody stability in the blood due to hydrophobicity of the drugs. One approach to solving this issue is the use of hydrophilic linkers. We developed a pendant type PEG linker which have two PEG chains between different functional groups. In this study, we prepared ADCs using cleavable pendant type PEG linkers incorporating a ValCit dipeptide for drug release and varying the PEG chain length to 4, 8, or 12 (hereafter referred to as PEG4, PEGS, and PEG12, respectively), and compared their efficacy.

Poster Presentation 2

Title
IL-2 mutein conjugated by releasable PEG for cancer immunotherapy

Date & Time
November 8 from 10:00 to 18:35, EST

Poster Number
#860

Speaker
Satoshi Kishida, Research scientist, NOF CORPORATION

Abstract
lnterleukin-2 (IL-2) is a well-established immune-oncology agent that activates CD8+ T cells. However, its therapeutic efficacy is limited due to its short half-life and IL-2 receptor alpha (IL-2Ra) capability. Moreover, the activation of CD8+ T cells by IL-2 is especially suppressed in the tumor microenvironment (TME) due to the acidic condition. Therefore, long-acting IL-2, which reduces IL-2Ra capability and enhances the Cytotoxic T lymphocyte (CTL) activity of CD8+ T cells is desired to enhance the therapeutic efficacy of IL-2. Here, we developed IL-2 mutein conjugated by releasable PEG that improves the pharmacokinetic profile and selectively activates CD8+ T cells residing in lymphoid organs and tumor microenvironment without inducing significant serious side effects.

See Also:

[View in PDF]

BACK